La Jolla Pharmaceutical Co: management transactions · United States · SEC (Form 4)

About La Jolla Pharmaceutical Co

La Jolla Pharmaceutical Company (ticker: LJPC) was a U.S. biopharmaceutical company focused on the development and commercialization of therapies for serious, often hospital-based diseases. Historically, LJPC was listed on the NASDAQ market in the United States, but in August 2022 the company was acquired by Innoviva. Following the transaction, La Jolla became a wholly owned subsidiary of Innoviva and its common stock was delisted from NASDAQ. For equity investors, this is a critical point: LJPC is no longer an independent publicly traded stock, although its legacy assets and historical disclosures remain relevant in SEC filings and in the broader Innoviva portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000119312522226088/d382789dex99a5b.htm?utm_source=openai)) The company was founded in California and was headquartered in La Jolla, California, reflecting its origins as a U.S.-based specialty pharma developer. Its business model centered on identifying unmet medical needs and translating them into products with clinical utility in high-acuity settings. The historical commercial platform was anchored by GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA® (eravacycline), used for complicated intra-abdominal infections. In addition to these marketed products, La Jolla pursued development programs in infectious disease, illustrating a pipeline strategy oriented toward medically complex, high-need niches rather than broad primary-care indications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000092046518000007/ljpc-201710xk.htm?utm_source=openai)) From a competitive standpoint, La Jolla was a specialty player rather than a diversified large-cap pharmaceutical company. Its addressable markets were highly competitive, with alternatives offered by larger hospital-focused and anti-infective franchises. The company’s differentiation depended on clinical relevance, targeted use in acute-care settings, and the ability to commercialize products in areas where physicians face meaningful therapeutic gaps. Geographically, the business was primarily U.S.-oriented, with product distribution in the United States handled through distributors and select wholesalers serving hospitals as end customers. That U.S. footprint and hospital-channel focus were central to the company’s operating model and its revenue generation before the acquisition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-201810xk.htm?utm_source=openai)) The most important recent corporate event was the 2022 acquisition by Innoviva, which effectively ended LJPC’s life as an independent listed issuer. For analysts and investors, that means any current reference to La Jolla Pharmaceutical should be read in a historical or subsidiary context, not as a standalone NASDAQ-listed name. In practical terms, the company’s legacy now sits inside Innoviva’s healthcare asset base, while the standalone LJPC ticker no longer represents an active publicly traded equity opportunity in the U.S. market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000119312522226088/d382789dex99a5b.htm?utm_source=openai))